Arcutis Biotherapeutics Inc (ARQT)

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

GlobeNewswire Inc.

Is AdaptHealth (AHCO) Stock Outpacing Its Medical Peers This Year?

Zacks Investment Research

Evaluating Arcutis Biotherapeutics: Insights From 5 Financial Analysts

Benzinga

Arcutis Appoints David Topper as Chief Financial Officer

GlobeNewswire Inc.

Are Medical Stocks Lagging AdaptHealth (AHCO) This Year?

Zacks Investment Research

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Arcutis Biotherapeutics, Inc. (ARQT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Zacks Investment Research

Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?

Zacks Investment Research

Wall Street Analysts See a 54.78% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High?

Zacks Investment Research

EQT, Genie Energy And Other Big Stocks Moving Lower On Monday

Benzinga

Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting

GlobeNewswire Inc.

New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction

GlobeNewswire Inc.

Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

GlobeNewswire Inc.

Wall Street Analysts See a 58.85% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High?

Zacks Investment Research

Is Arcutis Biotherapeutics (ARQT) Outperforming Other Medical Stocks This Year?

Zacks Investment Research

Arcutis to Present at the TD Cowen 44th Annual Health Care Conference

GlobeNewswire Inc.

Arcutis Announces Pricing of $150 Million Public Offering

GlobeNewswire Inc.

Arcutis Announces Proposed Public Offering

GlobeNewswire Inc.

Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan

GlobeNewswire Inc.

Breaking Down Arcutis Biotherapeutics: 4 Analysts Share Their Views

Benzinga

Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire Inc.

Avalo (AVTX) to Report Q4 Earnings: What's in the Cards?

Zacks Investment Research

Ginkgo (DNA) to Report Q4 Earnings: What's in the Cards?

Zacks Investment Research

Eton Pharma (ETON) to Report Q4 Earnings: What's in the Cards?

Zacks Investment Research

Sarepta (SRPT) to Report Q4 Earnings: Will It Beat Estimates?

Zacks Investment Research

Perrigo (PRGO) to Report Q4 Earnings: What's in the Cards?

Zacks Investment Research

Moderna (MRNA) Gears Up for Q4 Earnings: Will It Top Estimates?

Zacks Investment Research

Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire Inc.

Has Apellis Pharmaceuticals (APLS) Outpaced Other Medical Stocks This Year?

Zacks Investment Research

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Eli Lilly (LLY) Q4 Earnings Beat, Mounjaro, Zepbound Drive Sales

Zacks Investment Research

Assertio (ASRT) Stock Plunges 65% in 3 Months: Here's Why

Zacks Investment Research

MaxLinear Reports Q4 Results, Joins ING, Wolfspeed And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Benzinga

Arcutis to Present at the Guggenheim Healthcare Talks – 6th Annual Biotechnology Conference

GlobeNewswire Inc.

Are Medical Stocks Lagging AlloVir (ALVR) This Year?

Zacks Investment Research

Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial

GlobeNewswire Inc.

Verizon Posts Upbeat Earnings, Joins RTX, Procter & Gamble And Other Big Stocks Moving Higher On Tuesday

Benzinga

iRobot, AST SpaceMobile And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Benzinga

Arcutis Biotherapeutics, Inc. (ARQT) Moves to Strong Buy: Rationale Behind the Upgrade

Zacks Investment Research

ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids

GlobeNewswire Inc.

Best Momentum Stocks to Buy for January 11th (Revised)

Zacks Investment Research

Are Medical Stocks Lagging Amarin (AMRN) This Year?

Zacks Investment Research

Flexsteel Industries Posts Strong Preliminary Results, Joins Wipro, Sify Technologies And Other Big Stocks Moving Higher In Friday's Pre-Market Session

Benzinga

New Strong Buy Stocks for January 11th

Zacks Investment Research

Expert Outlook: Arcutis Biotherapeutics Through The Eyes Of 7 Analysts

Benzinga

Why DouYu International Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Benzinga

The Zacks Analyst Blog Highlights Allogene Therapeutics, Arcutis Biotherapeutics and C4 Therapeutics

Zacks Investment Research

3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying

Zacks Investment Research

Arcutis (ARQT) Up on FDA Nod for Zoryve in Seborrheic Dermatitis

Zacks Investment Research